Pasithea Therapeutics : Investor Presentation

Corporate Overview

October 2023

1

Company Disclaimer

Certain statements set forth in this presentation contain forward-looking statements that reflect the Company's plans, beliefs, expectations and current views with respect to, among other things, future events and financial performance (collectively referred to herein as "forward-looking statements"). Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause our actual results, performance or achievements or industry results to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements.

These include, but are not limited to, statements about the Company's ability to develop, obtain regulatory approval for and commercialize its product candidates; the timing of future IND submissions, initiation of preclinical studies and clinical trials, and timing of expected clinical results for our product candidates; the Company's success in early preclinical studies, which may not be indicative of results obtained in later studies or clinical trials; the outbreak of the novel strain of coronavirus disease, COVID-19, which could adversely impact our business, including our preclinical studies and any future clinical trials; the potential benefits of our product candidates ;the Company's ability to obtain regulatory approval to commercialize our existing or any future product candidates; the Company's ability to identify patients with the diseases treated by our product candidates, and to enroll patients in clinical trials; the Company's expectations regarding collaborations and other agreements with third parties and their potential benefits; the Company's ability to obtain, maintain and protect our intellectual property; the Company's reliance upon intellectual property licensed from third parties; the Company's ability to identify, recruit and retain key personnel; the Company's expected use of cash and cash equivalents to fund its operations; the Company's financial performance; developments or projections relating to the Company's competitors or industry; the impact of laws and regulations; the Company's expectations regarding the time during which it will be an emerging growth company under the JOBS Act; and other factors and assumptions described in the Company's public filings.

These statements are based on the Company's historical performance and on its current plans, estimates and projections in light of information currently available to the Company, and therefore, you should not place undue reliance on them. The inclusion of forward-looking information should not be regarded as a representation by the Company or any other person that the future plans, estimates or expectations contemplated by us will be achieved. Forward-looking statements made in this presentation speak only as of the date of this presentation, and the Company undertakes no obligation to update them in light of new information or future events, except as required by law.

2

Leadership Team with Broad Range of Experience and Success

Dr. Lawrence Steinman - Executive Chairman & Co-Founder

• Endowed Chair in the Neurology Dept. at Stanford University. Member of the National Academy of Sciences.
• Founded several successful biotech companies, including Neurocrine Biosciences Inc. and Tolerion Inc. (f/k/a Bayhill Therapeutics).
• Drug development pioneer in MS, with research that led to the development of the drug Tysabri.

Dr. Tiago Reis Marques - Chief Executive Officer & Co-Founder

• Fellow at Imperial College and lecturer at King´s College London.
• Renowned psychiatric researcher and lecturer with decades of experience in the biological mechanisms of mental health and brain disorders.

Dr. Graeme Currie - Chief Development Officer

• 30 years of drug development experience in both pharmaceutical and biotech companies.
• Senior leadership roles at Dynavax Technologies, Regeneron Pharmaceuticals, Inc., PDL BioPharma, Inc. and Gilead Sciences, Inc.
• Dr. Currie has successfully led drug development programs and has held key roles in the development of 7 approved drugs.

Daniel Schneiderman - Chief Financial Officer

• 20 years of experience in the capital markets and operations.
• Senior financial roles at translational biotech companies, including, MetaStat, Inc., Biophytis SA and First Wave BioPharma, Inc.

Diversified CNS Focused Product Pipeline

Program	Indication	Target	Target ID /	Lead	IND Enabling	Phase I	Upcoming
			Validation	Optimization			Milestones
PAS-004	Neurofibromatosis	MEK 1/2					IND filing
Type 1 (NF1) and
				2H 2023
	Noonan syndrome
							Lead candidate
	Amyotrophic Lateral	α5β1
PAS-003					selection 2H
Sclerosis (ALS)	Integrin
					2023
PAS-002	Multiple sclerosis	GlialCAM
(MS)
PAS-001	Schizophrenia	C4A

4

PAS-004

Next Generation MEK Inhibitor for the treatment of Neurofibromatosis Type 1 (NF1) and Noonan Syndrome

5